In this edition of Biotech Banter, Motley Fool contributor Brian Orelli and health care bureau chief Max Macaluso discuss an FDA delay for MannKind's Afrezza, clinical trial results from Amgen's T-VEC, up-and-coming biotech Agios, and the biotech "Tweet of the Week."
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
The latest from The Motley Fool's biotech show "Biotech Banter."
Brian Orelli has no position in any stocks mentioned. Max Macaluso, Ph.D. owns shares of Celgene. The Motley Fool recommends Celgene. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
3 Dividend Stocks to Double Up on Right Now
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.